Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) insider Stephen From acquired 12,500 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average price of $1.03 per share, with a total value of $12,875.00. Following the acquisition, the insider now owns 272,465 shares in the company, valued at $280,638.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Eyegate Pharmaceuticals, Inc. (EYEG) traded down 11.5893% on Thursday, reaching $0.9902. 689,688 shares of the company were exchanged. The firm’s market capitalization is $17.04 million. The stock’s 50-day moving average is $1.32 and its 200 day moving average is $1.86. Eyegate Pharmaceuticals, Inc. has a 12-month low of $0.90 and a 12-month high of $3.90.

Eyegate Pharmaceuticals (NASDAQ:EYEG) last issued its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.39). The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.22 million. Eyegate Pharmaceuticals had a negative return on equity of 840.69% and a negative net margin of 1,737.29%. On average, analysts forecast that Eyegate Pharmaceuticals, Inc. will post ($1.24) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/10/eyegate-pharmaceuticals-inc-nasdaqeyeg-insider-acquires-12875-00-in-stock.html.

A number of brokerages recently issued reports on EYEG. HC Wainwright set a $6.00 price objective on shares of Eyegate Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday. Noble Financial reiterated a “buy” rating on shares of Eyegate Pharmaceuticals in a report on Friday, May 19th.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.